Literature DB >> 27622041

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.

Roch Houot1, Philippe Gaulard2, Robert Schreiber3, Ira Mellman4, Olivier Lambotte5, Pierre G Coulie6, Thierry Fest7, Alan Korman8, Ronald Levy9, Margaret Shipp10, Karin Tarte7, Holbrook Kohrt11, Aurélien Marabelle12, Stephen Ansell13, Hervé Watier14, Andrea van Elsas15, Arun Balakumaran16, Frederick Arce Vargas17, Sergio A Quezada17, Gilles Salles18, Daniel Olive19.   

Abstract

In November 2015, the CALYM Carnot Institute held a 2-d workshop to discuss the current and future development of immunomodulatory antibodies for the treatment of lymphoma. Highlights from the workshop are presented in this article.

Entities:  

Keywords:  Immunomodulation; immunotherapy; lymphoma; programmed cell death 1 ligand 1; programmed cell death 1 receptor

Year:  2016        PMID： 27622041      PMCID： PMC5006908          DOI： 10.1080/2162402X.2016.1186323

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  74 in total

1.  A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P G Coulie; F Lehmann; B Lethé; J Herman; C Lurquin; M Andrawiss; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

2.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

3.  Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Authors:  John Stagg; Sherene Loi; Upulie Divisekera; Shin Foong Ngiow; Helene Duret; Hideo Yagita; Michele W Teng; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

4.  Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.

Authors:  Konstantinos Georgiou; Longyun Chen; Mattias Berglund; Weicheng Ren; Noel F C C de Miranda; Susana Lisboa; Marco Fangazio; Shida Zhu; Yong Hou; Kui Wu; Wenfeng Fang; Xianhuo Wang; Bin Meng; Li Zhang; Yixin Zeng; Govind Bhagat; Magnus Nordenskjöld; Christer Sundström; Gunilla Enblad; Riccardo Dalla-Favera; Huilai Zhang; Manuel R Teixeira; Laura Pasqualucci; Roujun Peng; Qiang Pan-Hammarström
Journal:  Blood       Date:  2016-03-30       Impact factor: 22.113

5.  Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.

Authors:  Julie Gertner-Dardenne; Remy Castellano; Emilie Mamessier; Slaveia Garbit; Eloïse Kochbati; Anne Etienne; Aude Charbonnier; Yves Collette; Norbert Vey; Daniel Olive
Journal:  J Immunol       Date:  2012-03-30       Impact factor: 5.422

6.  Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.

Authors:  Roch Houot; Holbrook E Kohrt; Aurélien Marabelle; Ronald Levy
Journal:  Trends Immunol       Date:  2011-09-08       Impact factor: 16.687

7.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

8.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

9.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

Authors:  Kerry J Savage; Stefano Monti; Jeffery L Kutok; Giorgio Cattoretti; Donna Neuberg; Laurence De Leval; Paul Kurtin; Paola Dal Cin; Christine Ladd; Friedrich Feuerhake; Ricardo C T Aguiar; Sigui Li; Gilles Salles; Francoise Berger; Wen Jing; Geraldine S Pinkus; Thomas Habermann; Riccardo Dalla-Favera; Nancy Lee Harris; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

10.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Authors:  Inge Verbrugge; Jim Hagekyriakou; Leslie L Sharp; Mara Galli; Alison West; Nicole M McLaughlin; Hélène Duret; Hideo Yagita; Ricky W Johnstone; Mark J Smyth; Nicole M Haynes
Journal:  Cancer Res       Date:  2012-05-08       Impact factor: 12.701
View more
  2 in total

Review 1.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 2.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.